MEDFORD, Mass. and ROCHESTER, N.Y., July 21, 2016 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a reproductive medical device company that was granted FDA clearance for the first in vivo, vaginal incubation system, the INVOcell™, today announced UR Medicine's Strong Fertility Center is the first fertility practice in Western and Upstate New York to offer a new alternative to in vitro fertilization – a vaginal incubation system that uses a woman's body, rather than a laboratory, to incubate her fertilized eggs.
The INVOcell Vaginal Incubation System received FDA approval in November 2015 and is available in only a handful of reproductive centers in the U.S. to date.
With in vitro fertilization (IVF), the eggs and sperm develop embryos in a laboratory petri dish that is placed in a temperature-controlled incubator until embryos are ready to be implanted in the uterus. The INVOcell device uses the women's vagina as a natural incubator to allow fertilization and embryo development for implantation.
INVOcell has been used in Europe, Africa and the Middle East. Clinical trials have shown it delivers pregnancy and live birth rates similar to traditional, standard IVF procedures.
"The INVO device offers a simplified, and therefore less costly, approach to fertility treatment," said Kathleen M. Hoeger, M.D., M.P.H., professor in UR Medicine's Department of Obstetrics and Gynecology and director of the Strong Fertility Center.
"One of the biggest challenges to helping couples achieve their dream of starting a family when they require the assistance of a fertility center is the cost of advanced treatments," Hoeger said. "A sizable proportion of patients need more help than just intrauterine inseminations but are reluctant to do IVF due to cost. The INVOcell approach offers a more affordable treatment option and thus improves access to fertility care for many more patients."
Bala Bhagavath, M.B.B.S., associate professor in UR Medicine's department of Obstetrics and Gynecology, will direct the INVOcell program at Strong Fertility Center. "Our practice is the longest-running in vitro fertilization center in upstate New York, and as an academic medical center fertility practice, we not only offer patients the latest treatments, but are active in the search for new and better ones," Bhagavath said. "Our physicians are proud to add INVOcell to our comprehensive range of fertility services and to bring this innovative treatment to patients in our region."
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
SOURCE INVO Bioscience, Inc.